A whole-animal platform to advance a clinical kinase inhibitor into new disease space
Masahiro Sonoshita(Hokkaido University), Arvin C. Dar(Memorial Sloan Kettering Cancer Center), Ross Cagan(University of Glasgow), Alexander M. Real(Tisch Hospital), Avner Schlessinger(Icahn School of Medicine at Mount Sinai), Peter M.U. Ung(Icahn School of Medicine at Mount Sinai), Lisa Silber(Icahn School of Medicine at Mount Sinai), Matthew A. Murray(Yale University), Alex Scopton(Tisch Hospital), Andres Y. Maldonado(Icahn School of Medicine at Mount Sinai)
Cited by 73
Related Papers
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
|Annual Review of Biochemistry|2011|389
Mechanistic Link between PKR Dimerization, Autophosphorylation, and eIF2α Substrate Recognition
|Cell|2005|367
Ligand discovery from a dopamine D3 receptor homology model and crystal structure
|Nature Chemical Biology|2011|303